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Abstract

EXPLORING THE METHYLATION STATUS OF RAI1 AND THE RAI1
CONSENSUS BINDING SEQUENCE
By Eri Kamura, B.S.
A thesis submitted in partial fulfillment of the requirements for the degree of Master of
Science at Virginia Commonwealth University.

Virginia Commonwealth University, 2009

Major Director: Dr. Sarah H. Elsea
Associate Professor, Departments of Pediatrics and Human and Molecular Genetics

Smith Magenis Syndrome (SMS) is a multiple congenital anomalies/ mental
retardation disorder caused by deletion or mutation of the RAI1 gene on chromosome
17p11.2. The majority of patients with SMS phenotypes have a deletion or mutation of
RAI1. However, some patients have been observed with SMS-like phenotypes and yet
have no deletions or mutations in the RAI1 gene. One possible explanation could be
aberrant methylation of RAI1 since RAI1 is present and yet may be silenced. In order to
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study this possibility, patient cell lines were treated with 5-Aza-2’-deoxycytidine. RNA
was extracted and real-time PCR was used to check the RAI1 expression status on the
cells. RAI1 is thought to be a transcription factor, but the DNA binding sequence is still
unknown. Sequences from ChIP-chip data were compared to identify a consensus
sequence. One gene which contained this consensus sequence was the chemokine-like
receptor-1 gene (CMKLR1), which was investigated by luciferase assay. CMKLR1
showed upregulation when co-transfected with RAI1.

viii

Chapter 1: Literature Review of Smith-Magenis Syndrome
and RAI1

Introduction
Smith-Magenis syndrome (SMS) [OMIM, #182290] is a multiple congenital anomalies
and mental retardation disorder. SMS is characterized by craniofacial and skeletal
anomalies, such as brachycephaly and midface hypoplasia, mental retardation, obesity,
distinctive behavioral phenotypes, including self-injurious behaviors, speech delay, and
sleep disturbance due to an inverted pattern of melatonin secretion. The incidence of
SMS is estimated to be around 1:15,000 – 25,000 but is thought to be under diagnosed
(8,9). SMS is commonly associated with an interstitial deletion involving chromosome
17p11.2 which spans ~3.7 Mb and includes the retinoic acid induced 1 (RAI1) gene.
Although the majority of patients with SMS share a common sized deletion, there have
been reports of patients with both smaller and larger deletions, along with patients that
have a mutation of RAI1 (8,21).

Physical Features
The phenotype of SMS becomes more pronounced and recognizable as individuals age
(12). Significantly decreased fetal movement in ~50% of pregnancies was noted in
prenatal histories for infants born at term. Craniofacial features that have been reported
include brachycephaly, a broad face, frontal bossing, synophrys, hypertelorism,
upslanting eyes, midface hypoplasia with a depressed nasal bridge, a tented upper lip
(cupid’s bow upper lip), prognathism, and low-set or abnormally shaped ears. Short
stature (<5th percentile) is commonly observed in young SMS patients (~67%), but most
resolve over time with individuals reaching the 10-25th percentile by adulthood (7,20).
Obesity is also common in teens and adult SMS patients. Other skeletal anomalies
include brachydactyly, scoliosis, fifth-finger clinodactyly, 2/3 toe syndactyly, elbow
limitations, forearm abnormalities, and vertebral anomalies (7,8,10). Otolaryngological
abnormalities such as chronic ear infections often associated with hearing loss, and a
hoarse voice are also common in these patients (8). Ophthalmologic anomalies are also
present in >60% of SMS patients, including myopia, strabismus, nystagmus,
microcornea, cataracts, iris anomalies, and retinal detachment (often resulting from
violent behaviors) (8).

2

Neurological and Behavioral Features
Most SMS patients have mild-to-moderate mental retardation with developmental delay
observed during childhood. Infantile hypotonia is common in these patients. Patient IQs
range between 20-78 with IQ decreasing as the child ages. Many of these children have
significant speech delay and motor delay, having better receptive language skills than
expressive language skills. Some neurological features include peripheral neuropathy,
pes cavus or pes planus, an abnormal gait, hyperactivity, balance problems, and most
characteristic of this syndrome is self-injurious behavior. Self-injurious behaviors
include head-banging, self-biting, polyembolokoilamania (insertion of objects into bodily
orifices), and onychotillomania (pulling out fingernails and toenails) (10). Other
behavioral characteristics include attention seeking behavior, impulsivity, an upper body
squeeze or “self-hugging”, temper tantrums, aggression, distraction, and disobedience (8).

Sleep Disturbance
The most characteristic finding of SMS is sleep disturbance and is reported in 75% 100% of patients (7). Sleep disturbances in individuals with SMS include difficulty
falling asleep, diminished REM sleep, reduced 24 -hour and night sleep, fragmented and
shortened sleep cycles with frequent nocturnal and early-morning awakenings, and
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excessive daytime sleepiness (8). These patients also have “sleep attacks” where they
suddenly fall asleep during evening meal time (6). These abnormal sleep patterns are due
to an inverted circadian rhythm of melatonin.

Melatonin and circadian rhythm
Melatonin is a naturally occurring hormone secreted by the pineal gland under the
influence of the suprachiasmatic nuclei (SCN) of the hypothalamus. The circadian
rhythm of melatonin secretion is endogenous; however, it is entrained by the light/dark
pattern of light received from the retina to the SCN (17). Melatonin plays an important
role in the bioregulation of circadian rhythms, sleep, mood, reproduction, and aging.
Concentrations of melatonin in the serum gradually increase from the onset of darkness
and peaks around 2 am to 4 am, and then decreases as the night ends. Potocki et al.
(2000) conducted a study measuring urinary excretion of 6-sulphatoxymelatonin (aMT6s),
the major metabolite of melatonin, showing SMS patients had abnormalities in the
circadian rhythm of aMT6s (17). This suggested that the disturbed sleep in these patients
could be caused by aberrations in the production, secretion, distribution or metabolism of
melatonin (17). β1-adrenergic antagonist therapy has been reported to help reduce the
sleep disturbances and improve behaviors (7). De Leersnyder et al. (2001) also
conducted a study to determine the circadian rhythm of melatonin in SMS patients. The
study found a phase shift in the circadian rhythm of melatonin in these patients in which
melatonin onset was around 6 AM, peak time was around 12 PM, and offset of melatonin
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was around 8 PM. Normal melatonin onset is around 9 PM, peak time is around 3:30
PM, and offset is around 6AM. The study showed how the melatonin secretion in SMS
patients is inverted compared to normal melatonin secretion patterns and suggests this
could be correlated to behavior problems SMS patients have (6). Tantrums, naps, and
sleep attacks all could correlate to the patients being tired because of their peak in
melatonin secretion during the day/evening time. Also, hyperactivity and attention
deficit could also be a result of the patients trying to fight the sleepiness induced by the
high melatonin (6).

RAI1
Approximately 90% of reported SMS cases have a deletion of the 17p11.2 region, while
10% have a mutation in the RAI1 gene. Deletions of this region are caused by abnormal
chromosomal recombination, which occurs in susceptible repeat-rich regions of the
genome, including chromosome 17p11.2. Chen et al. (1997) identified three low-copy
number repeats flanking the SMS common deletion region, called SMS-REPs (4).
Unequal meiotic crossovers mediated through nonallelic homologous recombination
occur between the proximal and distal SMS REPs that were identified resulting in ~70%
of the SMS deletion cases resulting in a common deletion of ~3.7Mb (8,18). Slager et al.
(2003) conducted a study where they looked at three individuals with strong clinical
suspicions of SMS but were negative for the 17p11.2 deletion. They sequenced three
genes that localized to the SMS critical region; developmentally regulated GTP binding

5

protein 2 (DRG2), RAS dexamethasone-induced 1 (RASD1), and RAI1 and found
mutations only in RAI1. This study supports the idea that haploinsufficiency of RAI1
leads to SMS (18,19,22).
The primary RAI1 transcript (GenBank AY172136, AJ271790; NM_030665.3;
NP_109590.3; OMIM*607642) consists of six exons which generate a ~8.5kb mRNA
and a 1906 amino acid protein (8). The protein contains a bipartite nuclear localization
signal, polyglutamine and polyserine tracts, and a C-terminal plant homeodomain (PhD)/
zinc-finger domain which is similar to that in the trithorax family of nuclear proteins (Fig.
1). Amino-acid sequence motifs representing these four domains in RAI1 are similar to
the transcription factor stromelysin-1 platelet-derived growth factor-responsive elementbinding protein, TCF20. This transcription factor is involved in growth and
neurobehavioral regulation and therefore suggests RAI1 might also be a transcription
factor(1,2,8).
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a)

b)

Fig. 1: RAI1 structure. a) The genomic structure of RAI1 with six exons. The light color in exon III-VI show the coding
exons. b) Protein structure of RAI1 with a bipartite nuclear localization signal, polyglutamine and polyserine tracts, and a Cterminal plant homeodomain (PhD)/ zinc-finger domain.
Source: Elsea and Girirajan 2008
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Chapter 2: Exploring the methylation status of RAI1

Introduction
Genomic DNA Methylation
There are several epigenetic modifications of DNA in the mammalian genome that affect
the transcription of genes. One of the most important, and the focus in this study, is DNA
methylation. DNA methylation is a mechanism that does not alter the gene product but
affects when and where the gene is expressed (5). DNA methylation in the promoter
region of a gene is associated with silencing of that gene (13). DNA methylation is now
considered the main contributor to the stability of gene expression status (15). There are
two kinds of methylation, which are maintenance DNA methylation, and de novo
methylation. DNA methylation involves the addition of a methyl group to the number
five carbon of the cytosine in a CpG dinucleotide. In mammals, methylation is essential
for normal development and also plays a key role in imprinting and X-chromosome
inactivation. The most common place for DNA methylation to occur in vertebrates is at
5’-CpG-3’ dinucleotides or CpG islands. A CpG island is defined as a region with at
least 200 bp with a GC percentage of over 50% and an observed/expected CpG ratio
greater than 60%. However, most CpG island promoter regions are protected from

8

methylation which leads to an expressed gene, whereas CpG sites in non-coding or
coding regions are often methylated which would lead to a silenced gene(5). DNA
methylation patterns in somatic cells are stably inherited due to the function of DNA
methyltransferases. These enzymes perform maintenance DNA methylation at
hemimethylated CpG sites after DNA replication (11). Genetic disorders such as PraderWilli syndrome and Angelman syndrome are results of altered genomic imprinting, in
which DNA methylation plays an important role (11). This suggests that it may be
possible that altered DNA methylation also plays a role in Smith-Magenis syndrome.

SMS-like patients
In the Elsea lab, there is a cohort of patients (~75% of patients referred to the lab),
referred to as “SMS-like”, that are clinically suspected to have Smith-Magenis syndrome
but do not have a molecular diagnosis of SMS. These patients have the classical clinical
phenotypes of SMS, including craniofacial and neurological abnormalities, specifically
self-injurious behaviors, hypotonia, and sleep disturbance but do not have a deletion of
17p11.2 or a mutation of RAI1. Previously, members of the Elsea lab have worked to
provide evidence for the occurrence of RAI1 haploinsufficiency in patients with SmithMagenis syndrome. RAI1 mRNA expression levels were measured using qRT-PCR
using SMS patient lymphoblast cell lines and control lymphoblasts. In the study, 7 out of
17 “SMS-like” patients were found to have a lower expression of RAI1, even though they
do not have a mutation or deletion of this gene (Fig. 2). (Lily Troung, Dissertation 2008)
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Normal

Del(17)(p11.2)

RAI1 Mutation

SMS-like

Fig. 2 RAI1 expression in SMS and SMS-like patient cell line. Mean results for each sample measured by real-time qRT-PCR and calibrated against
SMS282 to obtain relative RAI1 mRNA expression levels (Ct ratio). The relative mRNA expression level is numerically denoted above each sample.
For each sample, real-time qRT-PCR measurements were performed in triplicate and repeated at least twice.
Source: Lily Troung Dissertation 2008
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The methylation status of the RAI1 gene has never been investigated, and aberrant
methylation could be a likely explanation for the reduced RAI1 expression in the “SMSlike” patients. In order to investigate this issue, SMS patient cell lines were grown along
with control cell lines and treated with 5-Aza-2’-deoxycytidine, a demethylating agent,
and RAI1 expression was compared between the cell lines to identify any differences.
Demethylating agents like 5-Aza-2’-deoxycytidine inhibit methylation by being
incorporated into the nucleic acids of dividing cells where they act as inhibitors of DNA
methyltransferases (DNMT), which catalyze the methylation reaction. This results in the
expression of previously silenced genes (14). Treatment with 5-Aza-2’-deoxycytidine
that results in an increase in expression via real-time PCR suggests that DNA methylation
at that locus could be responsible for downregulation of that gene.
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Methods

Cell Culture
SMS patient cell lines (lymphoblasts) were taken from the frozen stock and thawed in a
37°C for ~20 min. RPMI with 10% FBS and 1% Pen/strep was also warmed in the 37°C
water bath for ~20 min. The cells in the cryovials were moved into a 25 cm2 cell culture
flask along with 10 ml of warmed RPMI. The cells were then maintained at 37°C in a
CO2 incubator.

Counting cells (lymphoblasts)
Cells were grown for about 3 weeks depending on the growth rate of all the cells in the
batch that was grown together. Cells were harvested when it was determined that the
slowest cell line had enough cells to seed them to a density of 500,000 cells per ml. Cells
were put in a 15 ml tube and centrifuged for 3 min at 12,000 rpm in a tabletop centrifuge.
The supernatant was discarded and the cell pellet was resuspended in 5 ml of new RPMI
with 10% FBS and 1% P/S. This was then pipetted up and down in order to break up any
cell clumps. Cells were dyed with tryphan blue and counted using a hemocytometer.
Cells were counted on the gridlines of the hemocytometer and the numbers were
averaged to get a final cell count.
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Splitting cells
The cells were split to a density of 500,000 cells/ml. They were split into three 25 cm2
per cell line and labeled 0 M, 5 µM, 10 µM. The cells were suspended in 5 ml of RPMI
with 10% FBS and 1% P/S. Cells were incubated at 37°C for 48 hrs. Cells were grown
in batches of about 3-4 cell lines which included control, RAI1 deletion, and “SMS-like”
cell lines. They were grown for approximately 3 weeks depending on how fast the RAI1
deletion and “SMS-like” cell lines grew.

5-Aza-2’-deoxycytidine treatment of cells
After the initial 48 hr incubation after the cells were split, 2 ml of the old media were
removed and replaced by 2 ml of fresh RPMI. The cells were then treated with 5-Aza-2’deoxycytidine. 25 µl of 5-Aza was put in the flasks labeled 5 µM and 50 µl of 5-Aza was
put in the flasks labeled 10 µM. Cells were then incubated for another 48 hrs at 37°C.
After the 48 hr incubation time, cells were put in a 10 ml tube and centrifuged for 3,min
at 12000 rpm. The supernatant was discarded, and cells were resuspended in 3 ml of PBS
in order to get rid of any remaining residue of 5-Aza-2’-deoxycytidine. The cells were
then centrifuged again for 3 min at 12,000 rpm. The supernatant was discarded, and the
cells were resuspended in RPMI with FBS and P/S and put in a 25 cm2 cell culture flask
and incubated at 37°C for 48 hrs.
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RNA extraction
After the 48 hr incubation period, RNA was extracted using the RNeasy mini kit
(Qiagen) according to the manufacturer’s protocol. An optional on-column DNase
digestion was performed using the RNase-Free DNase set (Qiagen) according to the
manufacturer’s protocol during the RNA purification process.

Spectrophotometer
RNA concentration was measured using spectrophotometry at 260 nm. This was done in
duplicates for each sample and the values were averaged to calculate the RNA
concentration.

Reverse transcriptase
First-strand cDNA synthesis was performed using SuperScript™ II RT (Invitrogen)
according to the manufacturer’s protocol. The maximum amount of RNA was used by
normalizing the RNA concentrations for each tube to the lowest concentration RNA. The
max amount of RNA from the lowest concentration RNA was added and the others were
adjusted in order to add the same amount of RNA to the reaction. Oligo(dT)12-18 (500
µg/ml) was used and the optional RNase OUT (40 units/µl) was added. RNaseH (2 units)
was then added after cDNA synthesis, and the reaction was incubated at 37°C for 20 min.

14

Real-time PCR
Real-time PCR was performed on the AB7500 FAST system. The master mix included
Universal PCR Master Mix, No Amp Erase® UNG (Applied Biosystems), Taqman Gene
expression Assay probes (ABI), and ddH2O. The cDNAs prepared from the SMS patient
cell lines were diluted 1:4 with ddH2O in order to minimize pipetting error. A total
volume of 6 µl of master mix and 4 µl of the diluted cDNA was added to each well on a
96 well-plate. Samples were done in triplicates and normalized to an endogenous
GAPDH. The results are shown with Relative Quantification values (RQ) which take
into account the endogenous GAPDH control and the calibrator. The RQ values are
automated calculations using the 7500 Fast PCR system (ABI). The mean and SD were
calculated for each study.
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Results

The methylation status of RAI1 was assessed by treatment of lymphoblast cell lines with
5-Aza-2’-deoxycytidine. Real-time PCR was used in this study to compare the RAI1
expression levels for control lymphoblast cells and control cells treated with the
demethylating agent. The methylation status of the “SMS-like” cohort of patients was
also investigated by comparing the expression levels of RAI1 between the patient cell
lines and the 5-Aza-2’-deoxycytidine treated cell lines. The lymphoblast cell lines were
grown in batches to minimize the variability and included cases with 17p11.2 deletions,
one or two “SMS-like”, and control controls, usually 3- 4 cell lines total per batch. All
samples were normalized with a GAPDH endogenous control probe in order to control
for RNA sample variability and also normalized to a control cell line grown with each
sample batch of cells in order to obtain relative expression levels (ΔΔCt ratio). One
major problem encountered while running these experiments is that the deletion cell lines
and some “SMS-like” cell lines were very slow to grow and sometimes did not grow at
all. These were then discarded from the batch leaving the batch with one less cell line for
evaluation and reducing the ability to compare expression levels.
The data include all usable data from a total of 35 cell lines that were grown in batches.
Cell lines were not included in the data if they did not grow, if the Ct values were higher
than 30, or if the Ct std error was >0.2, since these results were too variable to analyze.
All of the raw relative quantification (RQ) values shown are relative to one control line,
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from the batch the individual cell lines were grown in, as a calibrator. The RQ values
were then combined into one graph as shown in the figures.
The results for RAI1 expression of control lymphoblast cell lines treated with 5-Aza-2’deoxycytidine are shown in Fig. 3. The cell lines were not grown together, but were all
calibrated to their own normal untreated cell line. The trends are different between cell
lines but for all the cell lines there is no difference between untreated cells and drug
treated cell RAI1 expression. No increase in RAI1 expression is observed comparing the
5-Aza-2’-deoxycytidine treated cells to the untreated cells suggesting that RAI1 is not
normally methylated. Fig. 4 shows expression of RAI1 in RAI1 deletion patients relative
to a control set as 1. The cell lines are calibrated to the untreated control cell line in the
batch they were grown in. The results did not show lower expression in the RAI1
deletion cell lines as was expected since deletion patients are haploinsufficient for RAI1.
Instead RAI1 expression was as high as the controls. Fig. 5 shows 5-Aza-2’deoxycytidine treated RAI1 deletion cell lines but they do not show a consistent change in
expression. The cell lines are all calibrated to the untreated control cell line in the batch
they were grown in. Fig. 6 shows untreated “SMS-like” cell lines compared to the
control. In contrast to the preliminary data (performed by a previous student in the Elsea
lab), they do not display a decreased expression compared to the controls. All cell lines
were calibrated to the untreated control cell line from the batch they were grown in. Fig.
7 shows 5-Aza-2’-deoxycytidine treated “SMS-like” cell lines compared to the control.
The results of expression change from the drug treatment differ from cell line to cell line
and they are not consistent amongst themselves. There is no RAI1 expression increase
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that can be observed comparing the demethylating agent treated cell lines to the untreated
cell lines suggesting that methylation seems to not play a part in these “SMS-like” cell
lines. Fig. 8 shows the RAI1 expression of untreated control cell lines. The study was
repeated twice and the RQ values are calibrated to cell line 288. The results show large
variation in values even for the same cell lines. Control cell lines are inconsistent and
therefore suggests some other factor playing a role in RAI1 expression, like the timing of
when RNA is extracted.
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Fig. 3 RAI1 expression of 5-Aza-2’-deoxycytidine treated control cell lines. Cell lines shown are all control
cell lines which have been calibrated to the untreated line of each individual cell line. All untreated control cell lines are
shown as a raw RQ value of 1. Study was performed twice and error bars represent the SD of the two experiments. Cell line
211 does not have an error bar due to the fact it failed to grow during the repeat experiment. Experiment was done twice and
the qPCR was run in triplicate. RQ values are caluculated by normalizing to GAPDH and calibrating to the control.
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Fig. 4 RAI1 expression of untreated RAI1 deletion cell lines. Cell lines shown are RAI1 deletion cell lines with
the raw RQ value determined by calibrating against the control cell line from the same batch. There are no error bars due to
the fact that these cell lines are extremely difficult to grow since they are slow in growth and often die before reaching the
preferred density. RQ values shown are an average of triplicate wells from real-time PCR from a single study. RQ values are
caluculated by normalizing to GAPDH and calibrating to the control.
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Fig. 5 RAI1 expression of 5-Aza-2’-deoxycytidine treated RAI1 deletion cell lines. Cell lines shown are
RAI1 deletion cell lines treated with 5-Aza-2’-deoxycytidine. RQ values are determined by calibrating against the control cell
line from the same batches. Error bars on the control treated lines are the SD of the 6 control cell lines. The deletion cell lines
have no error bars since they were only done once with qPCR done in triplicate. RQ values are caluculated by normalizing to
GAPDH and calibrating to the control.
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Fig. 6 RAI1 expression of untreated “SMS-like” cell lines. Cell lines shown are all “SMS-like” patient cell lines
which were calibrated against a control grown with the individual cell lines. There are no error bars due to the fact the study
was done once in triplicate. RQ values are caluculated by normalizing to GAPDH and calibrating to the control.
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qPCR was done in triplicate. RQ values are caluculated by normalizing to GAPDH and calibrating to the control.
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Fig. 8 RAI1 expression of untreated control cell lines. All cell lines shown are control cell lines calibrated to cell
line 288. Samples were evaluated twice in triplicate and the error bars show the SD of the mean of those two triplicate values.
Cell line 211 does not have an error bar due to the fact that it failed to grow during the repeat study. Experiment was done
twice and qPCR was done in triplicates each time. RQ values are caluculated by normalizing to GAPDH and calibrating to the
control.
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Discussion
The methylation status of RAI1 has not been studied before. In this study, the RAI1
expression levels in control lymphoblast cells were compared to the expression of control
lymphoblast cells that were treated with 5-Aza-2’-deoxycytidine. If RAI1 was normally
methylated, the gene expression after treatment with the demethylating agent should
increase. However, the results from this study showed no increase in RAI1 expression in
these cell lines compared to the ones treated with 5-Aza. This suggests that RAI1 is not
normally methylated as was expected, as RAI1 is expressed in the population.
The other part to this study was to investigate whether the reason behind the cohort of
patients known as “SMS-like” having similar phenotypes as SMS patients was due to
aberrant promoter methylation of RAI1. The preliminary data did not have control cell
lines grown with each RAI1 deletion and “SMS-like” cell line and therefore needed to be
repeated. RAI1 mRNA expression levels were measured by quantitative real-time PCR
and compared with the same cell lines which were treated with 5-Aza-2’-deoxycytidine.
The results of this study were not consistent with the q-PCR preliminary data (performed
by a previous student in the Elsea lab). The range of the control cell lines were different
and also the “SMS-like” cell lines and RAI1 deletion cell lines did not exhibit reduced
RAI1 expression as previously shown. The deletion cases and “SMS-like” cases did not
have a decreased expression of RAI1. RAI1 deletion patients are haploinsufficient and
therefore should have a 50% reduced expression. Differences in results compared to
previous data may be due to the fact that RAI1 expression is sensitive to the growth
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period and can differ depending on when the RNA is extracted. The previous data may
have lacked accuracy since this was not considered. This problem was addressed by
growing cells in batches so as to minimize environmental differences and length of
growth. A control cell line was always grown with a deletion cell line and “SMS-like”
cell lines. However, the deletion cell lines and some “SMS-like” cell lines have a slower
doubling time, so the length of time they are grown is hard to control. These cells were
all started at the same time, harvested at the same time as soon as the slowest cell line
grew enough to be seeded at the required density, RNA extraction was done at the same
time, and reverse transcriptase was also done together. However, cell densities were
often not the same due to these differences in growth rates. Since the data was
inconsistent, the control cell lines were repeated to observe whether the RAI1 expression
would be similar every time. The results show that this is not the case and there is great
variability in RAI1 expression even in biological repeats. Since the control data was also
inconsistent, the method used for reverse transcriptase was investigated. A comparison
of RTs done with oligo dT, random primers, and both oligo dT and random primers
revealed no differences (Fig. 9). The conclusion from this experiment was that as long as
the same method was used, ie. just oligo dT or just random primers, the outcome would
not be different between cell lines. Oligo dT was used for all real-time PCRs in the study
as was in the preliminary study performed by a previous student. Next, to check for
technique errors in real-time PCR, cDNA prepared by the same individual was taken and
a real-time PCR was run along with another individual using the same cDNA. The
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results again showed no difference between the two real-time PCR expression levels, and
therefore real-time PCR technique error was ruled out (data not shown).
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Chapter 3: Identification of the RAI1 consensus binding
sequence: RAI1 regulates chemokine-like receptor 1

Introduction
Transcription factors are proteins that bind to specific DNA sequences and regulate
transcription of other genes. RAI1 is thought to be a transcription factor (8); however, it
is still unknown which genes RAI1 regulates or to what DNA sequence it binds. In order
to identify genes that RAI1 regulates, other members in the Elsea lab conducted a ChIPchip experiment, which is a combination of chromatin immunoprecipitation and
microarray technology on a genome wide scale. This technique will identify regions of
the genome where the RAI1 protein binds. The chip contains sequences that represent
promoters and regulatory regions of known human genes. An antibody to a Flag-tagged
RAI1was used to pull down any chromatin sequence that bound RAI1 (or a protein bound
to RAI1). The acquired data were processed through the Signal Map program in order to
narrow the putative RAI1 binding regions to the top ~200 candidates. Data from this
study identified a large number of promoter sequences to which RAI1 was potentially
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bound and thus, identified a cohort of genes that RAI1 may control. Consensus
sequences were identified by comparing the two shortest sequences from the top
candidate genes obtained from the ChIP-chip study. Potential target sequences were
identified and functionality studies using luciferase assays were initiated.
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Methods

Chip-chip
The Nimblegen standarad ChIP protocol was followed using the HG18 RefSeq promoter
array. The array has a 51 Mb coverage with 24,659 transcripts represented. Signal Map
software was used to identify most likely hits. (done by Stephen Williams, data not
shown)

Identifying 5-7bp binding sequence
In order to identify the RAI1 consensus binding region, the two shortest sequences from
the top ChIP-chip candidate genes were chosen. Microsoft Office Word was used to
compare these two sequences by using the “ctrl find” function and taking the first 5 bases
from the 1st sequence and trying to find the consensus sequence in the 2nd regulatory
region sequence. One base was shifted every time for a new search (Fig. 9). About 25
sequences of 5 ~7 bp in length were identified, and those sequences were then checked to
determine if they were known transcription factor binding sequences using the program
TESS and if they were present in the other gene promoter sequences in the ChIP-chip.
The top 2 unique candidate binding sequences were chosen.
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Amplifying putative binding region by PCR
Primers were designed to amplify approximately 200 bp around the 5~7 bp sequence
from genomic DNA. PCR was conducted with the program set to 4min initial denaturing
at 94°C, denature for 1 min at 94°C, and 35 cycles of 1 min annealing at temperature
according to different primers, and extension for 30 sec at 72°C, followed by a final
extension for 10 min at 72°C.
Primer Sequences for CMKLR1: (334 bp)
Forward – TAGTCATGTAGGATGCCA
Reverse - ATGCTGTGCTCTAGAGACA

Taq treatment
10 µl of gel extracted product was combined with 0.25 µl Taq (5 U/µl) and incubated at
72°C for 10 min. This was done to ensure the As were still on the end of the PCR
products for optimal cloning into the TA vector.

Cloning
The amplified PCR products were TOPO cloned into the TOPO2.1 vector according to
the manufacturer’s protocol (Invitrogen). PCR product that was Taq treated was used.
The TOPO cloned product was then transformed into E.Coli cells by adding 2 µl of the
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ligated product to 30 µl of One-shot chemically competent cells (Invitrogen) and
incubated on ice for 30 min. Then the cells were heat shocked at 42°C for 30 sec. They
were then immediately transferred to ice and 250 µl of S.O.C. medium was added. The
tube was then shaken horizontally at 37°C for 1 hr. After the incubation, 40 µl was
spread onto pre-warmed 50 µg/ml kanamycin plates. Colonies were grown and DNA
was prepared by standard methods (Fermentas). Once the insert was confirmed, the
purified DNA was cut with KpnI and XhoI for ligation into the pGL3 promoter vector.

Ligation into pGL3
The concentration of CMKLR1 sequence in the TOPO plasmid was evaluated by the
spectrophotometer. The following equation was used to determine the amount of insert
and vector to add to the reaction. Ligation and transformation were carried out according
to manufacturer’s protocol (Promega).

Maxi-prep
The pGL3 promoter vector with the CMKLR1 insert was maxi-prep’d for transfection.
The Qiagen plasmid purification protocol was followed, starting with inoculating 100 ml
medium. Cells were harvested, and the protocol for high-copy plasmids was used. The re-
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centrifugation step to remove the supernatant containing plasmid DNA was substituted
by filtering the supernatant from the step before through a Whatman filter 3 by gravity
flow. Subsequent steps were carried out as written in the protocol (Qiagen).

Growing cells (HEK293 cells)
Cells were grown in DMEM with 10% FBS and 1% Pen/Strep and maintained at 37°C in
a CO2 incubator.

Count cells (fibroblasts)
Cells were washed with 5 ml of PBS then treated with trypsin for 5 min at 37°C. The
sides of the flask ware tapped to ensure all cells come off bottom of the flask. 5 ml of
DMEM with 10%FBS was added to inactivate the trypsin. Cells were cetrifuged at
12,000 rpm for 2 min to form a pellet. The cell pellet was resuspended in DMEM with
FBS w/o P/S and counted using a hemocytometer. Cells (HEK293) were seeded at a
density of 1.6x105 cells in 2 ml of growth medium (DMEM w/FBS –P/S) in a 6-well
plate.
Transfection
The Invitrogen lipofectamine™ reagent protocol was used. The transfection procedures
were followed after scaling up for a 6-well plate. The cells were transfected with 1)
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CMKLR1, RAI1, and β-galactosidase, 2) CMKLR1 and β -gal, 3) RAI1 and β -gal, and 4)
with just β -gal by lipofection using Lipofectamine™ (Invitrogen) according to
manufacturer’s protocol. DNA (2 µg) was put in 100 ml of OptiMEM (Invitrogen) and
mixed with 25 µl lipofectamine reagent diluted in 100 µl OptiMEM (Invitrogen). The
mixture was incubated at room temperature for 40 min to allow complexes to form. The
complexes were then added to the HEK293 cells and incubated for 24 hrs at 37°C in a
CO2 incubator. Following transfection, cells were washed twice with PBS, then treated
with lysis buffer and cells were scraped off into a micro-centrifuge tube. They were then
centrifuged and the supernatant was collected.

Luminometer
Cell lysate (50µl) was placed into a 96-well plate and the lipofectamine reagent protocol
(Invitrogen) was followed along with the Galacto-Light System protocol (Applied
Biosystems).

Data analysis
The data were analyzed by taking the value from the luciferase and dividing that by the
value from the β-galactosidase. The CMKLR1+ RAI1 was set as 1 and the other values
were divided by the CMKLR1+RAI1 value. The mean and SD were calculated for each
study.
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Results

Putative RAI1 consensus DNA binding sequence

The ChIP-chip data revealed ~200 candidate gene promoters that bound RAI1 (or a
protein bound to RAI1). From the top ~200 genes, a 5~7 bp sequence was chosen via the
method listed above (Fig.10). The sequences that were most prevelant among the
top~200 candidate genes were chosen with the sequences TGAATTT and AGAATAT.
Variations of these two sequences; TGAAT, TGAATT, TGAATTT, AGAAT, AGAATA,
and AGAATAT were checked in the top 100 candidate genes for their prevelance. The
results revealed that the three variations of the sequence TGAATTT appeared in 74% of
the top 100 genes, and the three variations of the sequence AGAATAT appeared in 77%
of the top 100 genes.
From these sequences, the top candidate genes that were deemed to be relevant to SmithMagenis syndrome were selected to try and identify genes that RAI1 had a direct effect
on. The genes that were chosen for cloning were bone morphagenic protein 5 (BMP-5),
minichromosome maintenance protein 10 (MCM10), zinc finger protein 545 (ZNF545),
and beta-defensin 112 precursor (DEFB-12). While amplifying these potential RAI1
binding regions in the top candidate genes, DNA sequencing results of one of the genes
revealed a completely different gene, than the sequence that was expected originally.
Although this gene was not the gene the primers were designed for, it turned out to be the
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Chemokine-like receptor-1 gene (CMKLR1). The gene was then checked on the array
data to see if it was included in the top 200 candidate genes, and it was. This sequence
was then checked to see if the 5~7 bp potential binding sequence was included and was
found to have the AGAATT sequence in three places (Fig. 11). Since the sequence
amplified was in intron 2 of CMKLR1 and could be in a enhancer regulatory region, the
CMKLR1 sequence was further studied to analyze whether or not RAI1 had an effect on
its expression. The other candidate gene sequences were not able to be cloned into pGL3
due to wrong sequences, failure to PCR amplify, and unable to transfer into pGL3 from
the TOPO vector.
A luciferase assay was conducted by co-transfection of RAI1 and CMKLR1 regulatory
region sequence. The CMKLR1 sequence (Fig. 11) was put into a pGL3 vector that
contained the luciferase gene and an SV40 promoter, and β-galactosidase was used as a
control. The relative light units were measured and compared with HEK293 cells that
were transfected with 1) CMKLR1 regulatory region and β-galactosidase, 2) CMKLR1
regulatory region + β-galactosidase + RAI1, 3) RAI1 and β-galactosidase, and 4) βgalactosidase alone. This experiment was done twice, each done in duplicate (Fig. 12).
The results show an increase in relative light units when CMKLR1 regulatory region is
co-transfected with RAI1. However, when a confirmation was done to confirm the
presence of this gene on the array it was found that the gene that existed on the array was
the chemokine receptor like-1 gene (CCRL1) and not chemokine-like receptor-1
(CMKLR1). Also checking the array that was used in the ChIP-chip revealed that the
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CMKLR1 gene was not present on the array and therefore would not have appeared in the
ChIP-chip data. Thus, studies were continued on the CMKLR1 gene.
An additional transfection was done with RAI1 isoform-C to observe any fold change
differences due to the fact that this isoform lacks a NLS(nuclear localization signal) and a
PHD domain, which is thought to be the main binding domain for RAI1. The luciferase
activity was expected to stay the same as the controls and not increase since it lacks the
NLS and the PHD domain. The results show that the RAI1 isoform-C transfection with
CMKLR1 regulatory region sequence reveals increased luciferase activity compared to
the control but has decreased activity when compared to the full length RAI1 cotransfection.
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chr11:55698469-55698721
AAATCTCAGAAAAATGTATTAACTGATTGCATTTTTAAGTGAACAGTAAGAAAACGGAGATGGACATGAGCATTTTAAGCAAGCCCATC
CCTTAAAAATTTTTCCGTCTTTGGTAAGTTTTATTCATTCATTTGAATATTTATTTTTTCATATTTAGCATTCATTCTGCAGGTAATTGAAA
TTTTCAGTTAGATAAAATCCTTAAGGTTTTGAATCTTAAATTTTCTGTAAGTTAACACTGTGCCTTATTATG

chr19:41562918-41563180
GAGAGGTCTGTCTCCAATGAGACTGAATTTGTCCTGTCCTGCGTTCCTTCAGGAAAGAAATGGGATAAGCCCACCAGGGACCACCCT
GAGGCATCTTCTGTATCCCAAATTCTTTGATATATTAGTTAATACATGAAAGAATTTGTTCTTTCCTTAAGAATATAAAACTTTAGAAGAT
ATTTGAAAATGCCTCGGCAATCTGGTTTCATTTTGCAAACAATAGGATATGCATGAAATAGGAGATAAATGAAAAATCTGAGCTA

Fig. 10 Identifying the 5~7 bp RAI1 binding sequences. The two sequences shown are the two shortest sequences
from the top candidate genes given by the ChIP-chip results. The highlighted/underlined/italicized sequences are the matching
sequences in both regulatory region.
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chr12:107,223,494-107,223,656
GCCGCCAGTGTGATGGATATCTGCAGAATTCGCCCTTATGCTGTGCTCTAGAGACACCTCCAGATCCCTGTATCC
CCAGGCTCTGACAGACTCGGGAACCTGGAAACCACACAGTGTCTGCAGATGTTCCAGCCACAGGCCTGGCTGCC
AGCCCCAGGACAGAATTAGCTCCGTGTCAGGAGAGAATTTCCTCCCTGGTCCCACGCC

Fig. 11 Amplified CMKLR1 putative binding region sequence. The highlighted sequences are the putative RAI1 binding
sequences.
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Fig. 12 RAI1 co-transfection with CMKLR1 regulatory region. Results shown are from two experiments done
in duplicate. Error bars indicate SD (N=4).
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Discussion
Based on these studies, a gene potentially regulated by RAI1 is the chemokine-like
receptor-1 gene (CMKLR1) [OMIM, #602351], also known as ChemR23, DEZ,
MGC126105, or MGC126106 (Fig. 13). CMKLR1 is a G-protein-coupled receptor which
functions in skeletal system development, chemotaxis, immune response, and the Gprotein coupled receptor protein signaling pathway, and may also be associated with
obesity and the metabolic syndrome (3). Chemerin (TIG2), an adipokine which, upon
proteolytic cleavage is able to activate CMKLR1, is the endogenous ligand for CMKLR1
(16). Bozagolu et al. (2007) conducted a study in which they found both chemerin and
CMKLR1 expression to be elevated in adipose tissue (3,16). When the chemerin gene
expression was compared in normal and type 2 diabetic P.obesus, it showed that
chemerin was elevated in the obese animals and associated with the characteristics of
metabolic syndrome (3). In another study conducted by Martensson et al. (2005), it was
shown that the expression of chemerin and CMKLR1 is induced by all trans retinoic acid
(ATRA) from a luciferase reporter gene assay using ATRA stimulated cells; however, the
study failed to identify any RA-responsive element (16). Since chemerin and CMKLR1
are both induced by RA, we hypothesized that RAI1 may be playing a role in regulating
CMKLR1. This would be a reasonable hypothesis since one of the classic characteristics
of Smith-Magenis syndrome is obesity.
Although this was not the gene we expected to amplify, when we conducted a search on
the CMKLR1 sequence we amplified, we found the 6 bp consensus sequence (AGAATT)
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in 3 different places within the sequences and decided to further investigate the potential
effect of RAI1 on its expression (Fig. 12). In order to investigate whether RAI1 was
directly playing a role in the expression of CMKLR1, we conducted a co-transfection of
RAI1 and a fragment of the CMKLR1 gene containing the 6 bp potential binding
sequence cloned into the pGL3-promoter vector and conducted a luciferase assay to
evaluate the luciferase activity. The luciferase assay was done by co-transfecting RAI1 in
pDest26 (Invitrogen) and CMKLR1 in pGL3 (Invitrogen), which contains an SV40
promoter upstream of the luciferase gene. We expected to see an increase in expression
of CMKLR1 compared to a control transfection if RAI1 was binding to the CMKLR1
sequence and had a direct effect on CMKLR1 expression. The results from the luciferase
assay show an increased activity of luciferase when it was co-transfected with RAI1,
compared to the control transfections (Fig. 12). This suggests that RAI1 is directly
binding to the CMKLR1 regulatory region and is enhancing the expression of CMKLR1
or acting as a coactivator not directly bound.
Additionaly, a co-transfection was done with the CMKLR1 sequence in pGL3 and RAI1
isoform C in GFP. The RAI1 isoform C has 964 amino acids and lacks a NLS and PHD
domain. The results from this transfection show that the RAI isoform-C transfection still
shows increased luciferase activity. This suggests that the RAI1 isoform-C is still getting
into the nucleus probably due to effects of transfection and also that the PHD domain,
which was thought to be the main DNA binding domain for RAI1, is not the only DNA
binding domain. The RAI1 isoform-C may be binding via the Poly-Q domain, Poly-S
domain or another domain that is still unknown. RAI1 could also be acting non-directly.
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Fig. 14 CMKLR1 gene structure. There are 3 exons with the last exon being a coding exon. The red box in intron 2
represents the location of the potential regulatory region sequence that was amplified and inserted into pGL3.
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Chapter 4: Discussion

Exploring the Methylation Status of RAI1
The goal of this study was to investigate the methylation status of normal RAI1 and also
whether “SMS-like” patients had aberrant promoter methylation that was causing RAI1
expression to be reduced. From the study in Chapter 2, by treating the cells with a
demethylating agent, 5-Aza-2’-deoxycytidine, no increase in expression was observed in
control cell lines compared with non-drug treated cells. However, when “SMS-like”
patient cell lines were investigated for RAI1 expression, the study revealed no decrease in
RAI1 expression. To further investigate the reason for the inconsistent data, a technique
check was done on both reverse transcriptase and real-time PCR. Both revealed no
problem in the techniques. The fact that the expression of RAI1 looks different in the
data obtained from this study and the previous study may be due to the previous study
combining all cell line data from different experiments; cells were grown and RNA and
cDNA prepared at different times. . All possible trouble shooting was done, but this
project may need to be repeated in different cell types since the lymphoblastoid cells did
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not give consistent expression results. Future studies for this project include repeating
the RAI1 deletion cell line treatment and “SMS-like” cell line treatements since these
were only performed once. Also, conditions of the 5-Aza-2’-deoxycytidine treatment can
be tested by also looking at a gene known to be methylated. Another project would be to
synchronize the cells by serum starvation to observe any differences in RAI1 expression
during different times in the cell cycle. Since lymphoblastoid cells are transformed cells,
it is still unknown and studies still have not shown as to whether these are the optimal
cells to investigate methylation on. At this point a conclusion can not be made accurately
since some cell lines were only performed once, however, preliminarily the results seem
to suggest that aberrant RAI1 methylation does not play a role in contributing to SMS-like
patients. In the future, if the RAI1 promoter region is sequenced and cloned, bisulfate
sequencing or methylation specific PCR is another way to detect promoter methylation in
this gene.

RAI1 Consensus Binding Sequence
RAI1 is thought to be a transcription factor but nothing about its binding or function is
known. The project in Chapter 3 aimed to find a consensus binding sequence by
comparing the data sequences obtained from another lab member’s ChIP-chip study. The
comparison of the sequences revealed 2 distinct sequences (and their variations) in ~75%
of the top 100 gene candidates given by the ChIP-chip study. A gene accidently found
from this experiment is the chemokine-like receptor-1 (CMKLR1). This gene was
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accidently amplified but still contained the consensus sequence and also showed an
increase in expression when co-transfected with RAI1. The results from this study reveal
an interesting relation of CMKLR1 and RAI1, thus further studies should be done to
investigate its properties and interactions with RAI1.
Future studies for this project include repeating the RAI1 isoform-C luciferase assay, and
also conduct a RAI1 dosage response luciferase assay by varying the amount of RAI1
added. Future studies to investigate the exact RAI1 binding sequence should use site
directed mutagenesis. The 6 bp sequence in the CMKLR1 binding sequence could be
mutated and transfection would be repeated to compare results with the transfection with
the correct 6 bp binding sequence. If the expression decreases, this might be an
indication that the 6 bp potential binding sequence is correct. If the expression still
remains elevated, deletion constructs could be made by shortening either side of the
CMKLR1 sequence and repeating transfections with the deletion constructs until a
decrease in expression is found. An experiment that can be done to find direct evidence
of RAI1 binding could be to perform a electrophoretic mobility shift assay (EMSA).
This would show a band shift if RAI1 binds to the CMKLR1 sequence compared to a
band that contains only DNA and would support the direct binding of RAI1 and
CMKLR1.
For some future studies regarding the CMKLR1 gene, real-time PCR experiments can be
done to assess CMKLR1 expression in human adipose tissue obtained from liposuction.
The expression of CMKLR1 will be compared to the expression level of CMKLR1 in
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adipose tissue of subjects that are not overweight or obese. This study can also be done
in mice by assessing Cmklr1 expression in mouse adipose tissue from RAI1 transgenic,
RAI1 knockout, and non-transgenic mice. This study would show whether Cmklr1
expression is really elevated in the adipose tissue and whether there is a difference in
Cmklr1 expression in obese mice versus lean mice.
Some other studies are using the co-transfected cells with RAI1 and the CMKLR1
sequence and looking at CMKLR1 expression via real-time qPCR. This study would
show whether the expression if CMKLR1 is increased in the cells co-transfected with
RAI1 versus cells that have just CMKLR1. Increased expression levels of CMKLR1
would be expected in obese individuals in humans, and increase expression of Cmklr1
would be expected in RAI1 knockout mice since they are also obese.
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